Peter Zdziarski/LinkedIn
Feb 18, 2026, 15:24
Peter Zdziarski: How Glanzmann Thrombasthenia Suddenly Became ‘Mainstream’?
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
”Recently posted in the incredible Glanzmann Thrombasthenia Support Group (with almost 1 thousand patients, family members, and doctors!)
Just thinking out loud:
Has anyone else noticed how GT suddenly became ‘mainstream’?
And just as fast, a wave of unknown experts showed up out of nowhere?
I wish I knew why, but the point is this:
You are the expert in your GT. Your lived experience matters more than any trending take.
I know our community has been cautious about attention in the past. But let’s take advantage of the spotlight and turn it into new treatments and possibly even gene therapy!”
Stay updated with Hemostasis Today.
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target
-
Oct 7, 2026, 15:28Amir Samimi: Prognostic Value of Platelet Count in Resected HNSCC
-
Oct 7, 2026, 15:21Eloïse Laouenan: Bridging Immunity and Thrombosis in MVTE
-
Oct 7, 2026, 15:10Uthra Sundaram: Honouring Donors During International Plasma Awareness Week
-
Oct 7, 2026, 15:04Daniel Victor Ortigoza: Should Frail Older Patients With AF Switch From VKA to DOACs?
-
Oct 7, 2026, 14:53Susan Noone: Donor Turned Recipient Shares Lifesaving Transfusion Story
-
Oct 7, 2026, 14:49Aimee Burtenshaw: The Impact of the Infected Blood Inquiry on Hospital Transfusion Laboratories
-
Oct 7, 2026, 14:41Vikash Jaiswal: Does Timing Matter for Calcium in Pre-Eclampsia Prevention?